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Cardiac surgery associated acute kidney injury (CSA-AKI) is associated with poor
outcomes including increased mortality, length of hospital stay (LOS) and cost. The
incidence of acute kidney injury (AKI) is reported to be between 3 and 30% depending
on the definition of AKI. We designed a multicenter randomized controlled trial to test our
hypothesis that a perioperative infusion of sodium bicarbonate (SB) during cardiac surgery
will attenuate the post-operative rise in creatinine indicating renal injury when compared
to a perioperative infusion with normal saline. An interim analysis was performed after
data was available on the first 120 participants. A similar number of patients in the two
treatment groups developed AKI, defined as an increase in serum creatinine the first
48 h after surgery of 0.3 mg/dl or more. Specifically 14 patients (24%) who received
sodium chloride (SC) and 17 patients (27%) who received SB were observed to develop
AKI post-surgery, resulting in a relative risk of AKI of 1.1 (95% CI: 0.6–2.1, chi-square
p-value = 0.68) for patients receiving SB compared to those who received SC. The data
safety monitoring board for the trial recommended closing the study early as there was
only a 12% probability that the null hypothesis would be rejected. We therefore concluded
that a perioperative infusion of SB failed to attenuate the risk of CSA-AKI.
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INTRODUCTION
Cardiac surgery associated acute kidney injury (CSA-AKI) is
described as an acute worsening in kidney function observed after
cardiac surgery that is associated with poor outcomes (Bellomo
et al., 2008). Increased mortality, length of hospital stay (LOS)
and cost are all more likely in this setting (Chertow et al., 1998;
Lassnigg et al., 2004; Loef et al., 2005). The incidence of acute kid-
ney injury (AKI) is reported to be between 3 and 30% depending
on the definition of AKI. AKI requiring renal replacement ther-
apy, occurring in 1–5%, has a reported mortality rate ranging
from 60 to 90% (Frost et al., 1991; Chertow et al., 1998; Mangano
et al., 1998; Loef et al., 2005; Robert et al., 2010). Recent publica-
tions reported increased 30 day mortality for even mild levels of
acute renal failure (ARF) which do not require dialysis (Lassnigg
et al., 2004; Loef et al., 2005). Despite advances in medica-
tions, dialysis techniques and treatment strategies, the incidence,
morbidity and mortality associated CSA-AKI has not improved
significantly in 40 years. The pathophysiology of AKI is multi-
fold. Processes likely to contribute are toxins, metabolic factors,
ischemia-reperfusion injury, neurohormonal activation, inflam-
mation, and generation of reactive oxygen species (McCord, 1985;
Andersson et al., 1994; Lema et al., 1995; Rinder et al., 2003; Doi
et al., 2004; McCullough et al., 2006; Arora et al., 2008; Ascione
et al., 2008; Filsoufi et al., 2008; Greilich et al., 2008; Lecomte et al.,
2008; Fontaine et al., 2009). The prevention of AKI in this setting
is clinically and economically an important goal for CV surgery
and anesthesia programs. The multitude of causes makes it more
difficult to find a preventive intervention.
Preventive techniques for perioperative AKI have tradition-
ally focused on maintenance of hemodynamic stability, repletion
of blood and electrolyte imbalances and avoidance of nephro-
toxic drugs. Patients presenting for cardiovascular surgery were
found to be at increased risk for AKI. Several scoring sys-
tems have been developed to stratify patients at increased risk
(Higgins et al., 1992; Andersson et al., 1993; Chertow et al.,
1997; Fortescue et al., 2000; Brown et al., 2007). Few stud-
ies have examined preventive strategies for AKI in this setting.
In a 1995 meta-analysis, Conger reviewed all previous stud-
ies evaluating pharmacologic, dialytic, and nutritional attempts
at preventing ischemic ARF in a variety of clinical settings
(Conger, 1995). Commonly used therapies such as furosemide,
dopamine, and mannitol were found to offer no significant
reduction in rates of ARF (Conger, 1995; Bellomo et al., 2000).
Despite the lack of beneficial effects, an Austrian study in
2000 revealed that 25–35% of all cardiovascular surgery cases
in 38 European hospitals were using furosemide and low dose
Dopamine empirically (Lassnigg et al., 2000). Recent preventive
attempts included Fenoldopam, natriuretic peptides, hypertonic
saline, and immunomodulation revealing limited benefit with
few human studies included in those analyses (Conger, 1995;
Allgren et al., 1997; Block and Manning, 2002; Garwood et al.,
2003).
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The renal medulla receives a disproportionate share of renal
blood flow (<10% medulla vs. ∼90% cortex), making it an envi-
ronment of relative hypoxia and acidosis, where the urine first
becomes acidic. This region includes many of the active transport
pumps which require ATP to achieve maintenance of the renal
osmotic gradient. For these reasons it is themedulla which is often
the initial site of renal injury in perioperative settings involv-
ing ischemic acute tubular necrosis (ATN) (Myers and Moran,
1986; Brezis and Epstein, 1993). Cardiovascular surgery, espe-
cially when utilizing cardiopulmonary bypass, is considered to be
a high risk procedure for the development of AKI. Possible eti-
ologies include hypoperfusion after initiating cardiopulmonary
bypass, ischemia-reperfusion injury, activation of inflammatory
pathways, and reduction in oxygen supply due to hemodilution.
Hemodilution and the decline in perfusion pressure may fur-
ther aggravate oxygen delivery and medullary hypoxia. Protecting
the medulla by improving blood flow, oxygenation, and limit-
ing oxidative stress by free radical formation are important goals.
Sodium bicarbonate (SB), a slightly alkaline solution, has intrin-
sic natriuretic and diuretic effects in addition to its ability to
alkalinize tubular fluid (Atkins, 1986). It is our thought that these
properties contribute to increase oxygen delivery while reducing
free radical formation due to neutralizing acidosis in this vul-
nerable region of the kidney. These properties make SB a novel
anion in place of more traditional fluids used in the perioper-
ative period. In a pilot study, we had found that SB appears to
protect the kidney from ischemic injury in the setting of cardio-
vascular surgery. Rates of AKI, particularly in high risk patients,
were reduced using prophylactic bicarbonate based infusions in
place of traditional maintenance fluids (Fisher et al., 2004, 2005).
We hypothesized that a perioperative infusion of SB will
attenuate the post-operative rise in creatinine indicating renal
injury. The primary outcome, AKI, was determined based on
post-operative changes in creatinine values measured in the bicar-
bonate group vs. normal saline group. The maximum change in
glomerula filtration rate (GFR), LOS, incidence of dialysis, and
mortality rate were assessed as secondary outcomes.
METHODS
DESIGN
This was a multicenter, randomized, controlled trial of IV SB vs.
IV normal saline in high risk adult patients requiring cardiovas-
cular surgery to test the hypothesis that SB would be protective
against AKI post-operatively. We developed our inclusion criteria
based on studies describing patients at risk for developing severe
renal dysfunction after requiring cardiovascular surgery (Higgins
et al., 1992; Andersson et al., 1993; Chertow et al., 1997, 1998;
Fortescue et al., 2000; Thakar et al., 2005; Brown et al., 2007).
Inclusion criteria included planned receipt of cardiovascular
surgery as well as increased risk factors for AKI post-operatively,
including either an estimated GFR of <60ml/min/1.73 meters
squared or the combination of age greater than 70 years and com-
plex surgery (as defined in Table 1). Exclusion criteria included
eGFR of <15ml/min, emergency surgery, distal aortic surgery,
and pre-operative bicarbonate level>30mEq/l.
Patients undergoing cardiovascular surgery whomet the inclu-
sion and exclusion criteria were identified pre-operatively by
Table 1 | Inclusion and exclusion criteria.
Inclusion criteria
• Calculated GFR ≤ 60ml/min/m2 (MDRD) (OR)
• Any combination of two (2) of the following
• Age ≥ 70
• Complex surgery (any of the following)
- CABG/Valve - History of PVD surgery
- Redo operation - EF < 35%
- Deep hypothermic arrest - DM
- Prior kidney transplant - ≥ 2 valves
- Proximal Aortic surgery (i.e., ascending aortic aneurysm)
Exclusion criteria
• Age < 18
• Pre-existing ESRD (dialysis patients)
• Pre-op GFR ≤ 15ml/min/m2
• Pre-op bicarbonate level ≥ 30 mEq/L
• Emergency surgery (unable to effectively consent)
• Pregnancy
• Heart transplant (OHT)
• Distal Aortic surgery (i.e., descending aortic aneurysm)
• Procedure does not require central venous access
CABG, Coronary Artery Bypass Graft; DM, Diabetes Mellitus; EF, Ejection
Fraction; ESRD, End Stage Renal Disease; GFR, Glomerular Filtration Rate;
MDRD, Modification of Diet in Renal Disease Study; OHT, Orthotopic Heart
Transplantation.
study personnel who explained the study protocol and obtained
written informed consent for the trial. Patients eligible for
the study were identified more than 12 h prior to elective or
urgent surgery to allow enough time to make an informed deci-
sion regarding the trial. Qualifying patients were randomized
to receive either SB or normal saline (controls) as periopera-
tive infusions. Subjects enrolled in the trial received a weight
based pre-operative bolus of the designated fluid followed post-
operatively by a weight based infusion of the designated fluid for
22 h. Serum creatinine levels were obtained pre-operatively and
then on a daily basis for at least 72 h post-operatively. The serum
creatinine level was measured daily using the Jaffe method. Other
data collected during the trial period included length of stay in the
hospital and need for dialytic therapy for treatment of AKI dur-
ing hospitalization. The protocol for this prospective randomized
controlled multicenter trial was approved by the Wake Forest and
Ohio State School of Medicine’s Institutional Review Boards and
registered with Clinical trials.gov (NCT0048435).
SURGICAL TECHNIQUE
All surgical procedures were performed through a median
sternotomy. Equipment used during cardiopulmonary bypass
included: a roller pump system (Terumo system I) with trillium
coated tubing (Medtronic), a membrane oxygenator (Affinity tril-
lium coated, Medtronic’s), and an arterial filter (351 20 micron by
Medtronic). The circuit was primed with Plasmalyte A, as well
as 10,000 units of unfractionated heparin, 25mg of Mannitol,
and 50mEq SB with a final pump volume of ∼700ml. The
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patients were resuscitated with crystalloids (lactated ringer’s or
normal saline solutions), blood products or colloids (albumin
5%). The patient’s maximum blood glucose levels were main-
tained at<190mg/dl using insulin infusions± boluses as deemed
necessary. Throughout the procedure, the patients’ anesthetic
was maintained using volatile anesthetics, benzodiazepines, and
narcotics (fentanyl, morphine, and methadone) as per anes-
thesiologists’ preference. Perioperative hemodynamic manage-
ment targeted either the baseline cardiac output (CO) prior to
induction or a CO >2.1 l/min/m2 and a mean arterial blood
pressure >60mmHg. The intraoperative fluid management was
directed by the treating anesthesiologist and documented. All
clinical data was collected prospectively and entered into a com-
puterized database by the research team.
ADMINISTRATION OF IV BICARBONATE AND IV NORMAL SALINE
Those patients allocated to the normal saline arm (controls)
underwent a protocol consisting of an initial bolus consisting
of 0.154M NaCl (NS) at 5.0ml/kg (or a maximum bolus dose
of 500ml to avoid excessive fluid overload) given over 15min
prior to initiation of cardio-pulmonary bypass. Following the
bolus, these patients were infused with NS (0.154M) at a rate
of 1.0ml/kg/h (or a maximum rate of infusion of 125mL/min to
avoid excessive fluid overload) for a total of 10 h, and decreased
to 0.4ml/kg/h for a remaining 12 h; essentially until the fol-
lowing day. Those patients allocated to the SB (NaHCO3) arm
received a 0.150M NaHCO3 solution prepared in a sterile water
base. Bicarbonate solution was prepared by a central pharmacy
at each site. Blinding of clinical staff to treatment arm was not
performed as the data collected in the study was objective data.
This protocol consisted of an initial bolus of 0.150M NaHCO3
at 5.0ml/kg (or a maximum bolus dose of 500ml) given prior
to initiation of cardio-pulmonary bypass, followed by a 0.150M
NaHCO3 infusion at a rate of 1.0ml/kg/h (or a maximum rate
of infusion of 125mL/min) for a total of 10 h followed by a
NaHCO3 infusion of 0.4ml/kg/h for another 12 h, as was done
with the NS treated patients. The goal bicarbonate dose in this
study was ∼3.0mEq/kg. This dose was based on what our group
found to be efficacious in our previous studies (Fisher et al., 2004,
2005). The study protocol included mechanisms to adjust the
bicarbonate infusion rates based on post-operative lab values. The
bicarbonate infusion rate was decreased by one half (1/2) for all
patients whose serum bicarbonate level was greater than or equal
to 30mmol/L post-operatively. This half dose infusion was con-
tinued until the serum bicarbonate returned to a level less than
30mmol/L at which time the rate was increased back to the previ-
ous level. For any patient with a post-operative serum bicarbonate
level greater than or equal to 35mmol/ml the infusion rate was
decreased to 10mL per hour (KVO) until the bicarbonate level
dropped to less than 30mmol/ml at which time the infusion rate
was increased back to previous levels.
This protocol consisted of ∼22 h of IV study infusion. Any
other IV fluid that the respective surgeons or anesthesiologists
deemed necessary was allowed as part of routine patient man-
agement. For those patients felt to be volume overloaded, the
randomized fluid was reduced to 10mL per hour until the clinical
conditions allow the higher rate to be resumed.
ANALYTIC PLAN
The primary outcome of the trial was to determine the rate of
AKI in the study population. The study sample size was deter-
mined based on previous information in a high risk population.
Historic data reported rates of ARF, defined arbitrarily as a change
in SCr≥ 1.0mg/dL, to be∼11.7% in patients treated with sodium
chloride (SC) and 2.7% in patients treated with the bicarbonate
solution (Fisher et al., 2004). To observe these differences between
treatment groups in ARF with 90% power and a 5% type one
error rate, ∼360 patients (180 in each randomized group) would
need to be enrolled in the trial.
After the study was initiated, a consensus definition of AKI was
introduced in 2004 (RIFLE) and subsequently modified based on
the AKIN staging system (Mehta et al., 2007). This system defines
stage 1 of AKI as a 1.5 fold or ≥0.3mg/dl increase in the serum
creatinine level from baseline. After the initiation of the trial the
AKIN staging system had become a clearly defined reference for
AKI and in consultation with our DSMB, but prior to data analy-
sis, the AKIN definition of stage I AKI was chosen as the primary
means to determine the presence of AKI. For analytic purposes,
we evaluated our results based on three definitions of ARF: ARF
defined as an increase in serum creatinine (SCr) by 1mg/dl in
72 h, ARF (AKI) defined as an increase of 25% in SCr, and ARF
(AKI) defined as an increase in SCr of 0.3mg/dl.
Secondary endpoints of interest include the maximum change
in estimated serum creatinine and the glomerular filtration rate
(GFR) during the first 72 h post-operatively, LOS, incidence of
dialysis (HD) and mortality.
INTERIM ANALYSIS AND DETERMINATION OF FUTILITY
At the interim time, we tested the hypothesis of a difference in the
proportion of patients with any AKI between treatment groups,
as described by the AKIN staging system (AKI as a 1.5 fold or
≥0.3mg/dl increase in serum creatinine from baseline). Data
from 120 patients was available for analysis (2 patients did not
have post-surgery creatinine measurements recorded at OSU—
one in each treatment arm). AKI was observed in 31 (26%) of
patients, with nearly equal numbers in each randomized group
[14 in the normal saline (24%), 17 in the SB group (27%)], result-
ing in an interim test p-value (chi-square test) of 0.95. Given this
information, we could clearly state that early efficacy was not met.
In fact based on this information, conditional power based on
the effect size determined with the 120 patients accrued, was esti-
mated to be only 12%. Given this very low estimated conditional
power, we, along with our data and safety monitoring commit-
tee, recommended closing the trial and reporting on the current
study.
PRIMARY AND SECONDARY OUTCOME ANALYSIS
The primary analysis of AKI rates between treatment groups was
evaluated by the chi-squared test and included estimates of the
relative risk and associated 95% confidence intervals. Secondary
outcomes included length of stay and maximum change in GFR
which were compared by a two-sample t-test (without assuming
equal variances) or by the chi-square test for categorical outcomes
such as mortality and incidence of dialysis. All tests were two-
sided and considered significant at the 0.05 level. Analyses and
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data management were performed using SAS software, Version
9.2 of the SAS System. Copywrite, SAS Institute Inc., Cary, NC,
USA.
RESULTS
ACUTE KIDNEY INJURY AND OTHER RENAL OUTCOMES
Patients were recruited to the study between August 2006 and
February 2011. Patient characteristics of the study population are
shown in Table 2. The average patient age was ∼70 years and the
majority of the participants were Caucasians. The type of surgery
performed included coronary artery bypass grafting (alone or
in combination with valvular surgery), valvular surgery, aortic
(ascending and aortic arch) as well as placement of ventricular
assist devices.
Due to slow enrollment, the study team and independent
clinical ethicist agreed to perform an interim analysis once 120
subjects were enrolled to determine if treatment efficacy had
been met. A total of 123 patients were enrolled between the
two centers to either receive intravenous SB (n = 64) or SC
(n = 59) infusions. As described earlier, accrual to this study was
stopped early due to no evidence of efficacy (See Interim analy-
sis). Data from 120 patients were available for analysis (2 patients
did not have post-surgery creatinine measurements recorded at
OSU;–one in each treatment arm). One patient suffered from
infiltration of SB around the peripheral intravenous access site.
The infiltration was treated, and the patient dropped out of
the study.
A similar number of patients in the two treatment groups
developed AKI, defined as an increase in serum creatinine the first
48 h after surgery of 0.3mg/dl or more. Specifically 14 patients
(24%) who received SC and 17 patients (27%) who received SB
were observed to develop AKI post-surgery, resulting in a relative
risk of AKI of 1.1 (95%CI: 0.6–2.1, chi-square p-value= 0.68) for
patients receiving SB compared to those who received SC. AKI in
the first 72 h occurred in 42 patients [22 patients (38%) in the
SC group and 20 patients (32%) in the SB group] resulting in
an estimated relative risk of 0.9 (95% CI: 0.5–1.4). AKI defined
as an increase of 25% or more in serum creatinine (AKI25) in
the first 24 or 48 h was also not substantially different between
groups (Table 3). Moreover, ARF defined in the original study
design, was not improved post-surgery by the use of SB. ARF was
not frequently observed; only 3 patients (5%) in the SC group
and 7 patients (11%) in the SB group had ARF (RR = 2.2; 95%
CI: 0.6–8.0). A sub analysis of patients who had contrast during
surgery, did not provided a substantial change to these conclu-
sions concerning differences in AKI or ARF post-surgery between
these groups.
OTHER OUTCOMES
We observed a similar number of deaths (10 in the SC group and
9 in the SB group) and patients in need for post-operative dial-
ysis (5 in the SC group and 4 in the SB group) in both groups.
Further, the number of days spend in the hospital did not differ
substantially between the treatment groups with an average of
14.2 days [standard deviation (sd) = 15.4] in SB patients and
14.6 days (sd = 14.2) in SC patients (t-test assuming unequal
variances p-value = 0.88).
Table 2 | Patient demographics and pre-surgery clinical
characteristics.
Demographics Sodium Sodium
chloride (n = 59) bicarbonate (n = 64)
Age, years* 69.7 (13.5) 70.2 (12.6)
Sex
Female 16 (27%) 30 (47%)
Male 43 (73%) 34 (53%)
Race
White 47 (80%) 57 (89%)
Black 9 (15%) 5 (8%)
Unknown 3 (5%) 2 (3%)
Weight, kg*a 90.2 (19.5) 85.4 (18.4)
Site
OSU 36 (61%) 35 (55%)
Wake Forest 23 (39%) 29 (45%)
MEDICAL HISTORY AND COMORBIDITIES
Previous CV surgery 13 (22%) 22 (34%)
Previous PVD surgery 5 (8%) 7 (11%)
History of kidney disease 2 (3%) 0 (0%)
History of HTN 51 (86%) 51 (80%)
History of DM 26 (44%) 30 (47%)
History of COPD 6 (10%) 12 (19%)
History of MI 13 (22%) 10 (16%)
MEDICATION
Aprotinin 14 (24%) 16 (25%)
Amicar 18 (31%) 13 (20%)
Contrast 30 (51%) 34 (53%)
MEASURES OF KIDNEY FUNCTION
Plasma creatinine
mg/dl*b
1.2 (0.5) 1.0 (0.4)
Plasma HCO3*c 25.8 (3.1) 26.1 (3.0)
Plasma CA*d 8.2 (1.8) 8.2 (1.8)
Plasma K*e 4.3 (0.4) 4.2 (0.4)
COPD, Chronic Obstructive Pulmonary Disease; DM, Diabetes Mellitus; HTN,
Hypertension; MI, Miocardial Infarction; PVD, Peripheral Vascular Disease.
*Mean (standard deviation); aavailable on 59 (SC) and 63 (SB); bavailable on 57
(SC) and 62 (SB); cavailable on 55 (SC) and 61 (SB); d available on 48 (SC) and 57
(SB); eavailable on 57 (SC) and 61 (SB).
DISCUSSION
In this trial, we did not find a benefit of IV SB administration in
decreasing the rate of AKI compared to placebo. The incidence
of AKI defined as an increase of creatinine by 0.3mg/dl in our
study was not different between study groups (24% in the SC
group, and 24% in the SB group). Moreover, ARF, as defined in
the original study design, was rare and not improved by the use
of SB. The incidence of ARF observed in our study was lower
than historical data indicated; only 3 patients (5%) in the SC
group and 7 (11%) patents in the SB group had ARF compared
to 11.7% reported. Based on our data and the definition of ARF
stated above, we observed no beneficial effect of a perioperative
SB infusion, but rather a suggestion of increased incidence of ARF.
During the enrollment of our patients, a pilot study was published
by Haase et al., indicating a beneficial effect of a perioperative
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Table 3 | Outcomes by treatment group*.
Sodium Sodium Relative
chloride (n = 59) bicarbonate (n = 64) risk (95% CI)
PRIMARY ENDPOINT
AKI 0.3mg/dl (72h)
No 36 (62%) 42 (68%) 1.0
Yes 22 (38%) 20 (32%) 0.9 (0.5–1.4)
SECONDARY ENDPOINTS
ARF 1.0mg/dl (72h)
No 55 (95%) 55 (89%) 1.0
Yes 3 (5%) 7 (11%) 2.2 (0.6–8.0)
AKI 0.3mg/dl (48h)
No 44 (76%) 45 (73%) 1.0
Yes 14 (24%) 17 (27%) 1.1 (0.6–2.1)
AKI 25% change (48h)
No 47 (81%) 44 (71%) 1.0
Yes 11 (19%) 18 (29%) 1.5 (0.8–3.0)
AKI 25% change (72h)
No 38 (66%) 41 (66%) 1.0
Yes 20 (34%) 21 (34%) 0.9 (0.6–1.6)
Hemodialysis
No 50 (91%) 58 (94%) 1.0
Yes 5 (9%) 4 (6%) 0.7 (0.2–2.5)
Death
No 48 (83%) 54 (86%) 1.0
Yes 10 (17%) 9 (14%) 0.8 (0.4–1.9)
Length of Stay
Mean (std) 14.6 (14.4) 14.2 (15.4) 0.43 (–5.1–5.9)
SUBSET WITH CONTRAST
AKI 0.3mg/dl (48h)
No 21 (75.0) 22 (66.7) 1.0
Yes 7 (25.0) 11 (33.3) 1.3 (0.6–3.0)
AKI 0.3mg/dl (72h)
No 19 (67.9) 22 (66.7) 1.0
Yes 9 (32.1) 11 (33.3) 1.0 (0.5–2.1)
AKI 25% change (48h)
No 23 (82.1) 21 (63.6) 1.0
Yes 5 (17.9) 12 (36.4) 2.0 (0.8–5.1)
AKI 25% change (72h)
No 20 (71.4) 21 (63.6) 1.0
Yes 8 (28.6) 12 (36.4) 1.3 (0.6–2.7)
ARF 1.0mg/dl (72h)
No 27 (96.4) 29 (87.9) 1.0
Yes 1 (3.6) 4 (12.1) 3.4 (0.4–28.7)
AKI, Acute Kidney Injury; ARF, Acute Renal Failure.
*Outcomes missing on 3 individuals (1 in the SC group and 2 in the SB group),
except for death where it is missing in 2 individuals (1 in each group).
infusion of SB to prevent an increase of serum creatinine after
cardiac surgery (Haase et al., 2009). The authors defined acute
renal dysfunction as an increase in plasma creatinine concen-
tration of greater than 25% from baseline within the 1st 5 days
after cardiopulmonary bypass. Considering a sample size of 100
patients, they observed the risk of developing acute renal dysfunc-
tion to be reduced by 20%when using a perioperative bicarbonate
infusion. Due to slow enrollment and time for an interim analy-
sis, we analyzed our data in 2011, showing no beneficial effect of
a perioperative SB infusion. Having a comparable study popula-
tion and protocol to Haase’s study, we analyzed our data using the
Haase’s definition of acute renal dysfunction. In contrast to their
study, we observed the change in creatinine over 72 h following
cardio-pulmonary bypass, with no beneficial effect of the periop-
erative administration of SB (Table 3). In an attempt to explain
the difference in outcome, we closely compared the study pro-
tocols of Haase’s and our study. Both protocols targeted a high
risk population, started the administration of the study solution
as a bolus followed by a maintenance infusion prior to initiating
cardio-pulmonary bypass, and continued the infusion into the
post-operative period. The protocols differed in the bolus amount
(0.5 vs. 0.75mmol/kg), and time administered (60 vs. 20min),
and the total amount of SB (4 vs. 3mmol/kg), as well as the total
amount of fluid administered (1250ml regardless of weight vs. up
to 2000ml based on weight). Our study observed changes for 72 h
following surgery, whereas Haase et al. studied their patients for
an extra 2 days. Whether any of these differences are responsible
for the difference in outcome remains debatable.
Nevertheless, our results are more in line with the results
of studies recently published, that were conducted in a larger
patient population (Heringlake et al., 2012; Haase et al., 2013;
McGuinness et al., 2013). Two of these studies are multicenter
randomized trials including a total of 777 patients, while the
third study is a prospective observational cohort study includ-
ing 304 patients (Heringlake et al., 2012). Since both randomized
controlled studies used the same study protocol as Haase’s pilot
study, it seems unlikely that our study protocol is solely respon-
sible for our inability to show a beneficial effect. We considered
the possibly that the standard of care changed over time, and
that SB was more effective in a historical patient population,
since the initial beneficial effects of SB were observed in con-
trast induced nephropathies (Motohiro et al., 2011; Ueda et al.,
2011). We posited that the standard of care changed to delay
cardiac surgery after exposure to contrast. We performed a sub
analysis on our study population recently receiving contrast to
see whether SB has any beneficial effect in this subset of patients.
We identified 28 patients in the SC and 33 patients in the SB
group. After applying the 3 definitions of AKI mentioned above,
we did not find any benefit in SB administration, but rather
a trend of increased likelihood to develop AKI (Table 3). The
prospective observational study differs from other studies men-
tioned in targeting all patients presenting for cardiac surgery
without preference for patients at risk to develop kidney injury
post-operatively (Heringlake et al., 2012).
A clear limitation of our study is the number of patients that
we eventually enrolled. Our initial sample size, based on an inci-
dence of renal failure of 11.7%, was 360 patients. With any lack
of benefit demonstrated in the interim analysis, we terminated
our study early. While even larger studies could not demonstrate
a beneficial effect of perioperative treatment with SB, Haase’s
most recent work observed a trend of increased mortality in
patients receiving SB (Haase et al., 2013). They have therefore
recommended abstaining from using SB infusions as prophylaxis
to ameliorate CSA-AKI. Based on our and currently available
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findings, we cannot recommend the prophylactic use of a peri-
operative SB, or suggest the intervention to be tested on a larger
study population. The most likely explanation for the lack of ben-
efit of a perioperative SB infusion is the multifactorial etiology
of CSA-AKI, and a modification of only one contributing factor
insufficient to impact the development of renal failure.
In conclusion, patients undergoing cardio-vascular surgery
exposed to cardiopulmonary bypass represent the second most
common group of patients treated in intensive care unit settings
to develop AKI (Uchino et al., 2005). Based on our previous
experience, we tested the hypothesis that the administration of
a prophylactic perioperative SB infusion will alter the devel-
opment of AKI in a high risk population presenting for high
risk surgery. We were unable to demonstrate a beneficial effect
applying historic or recently revised definitions of AKI.
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